Eli Lilly and Company

Steven Wayne Pedersen

David Scott Coffey

James Allen Monn

Concepcion Pedregal-Tercero

David Michael Remick

Xinchao Chen

Susan Marie Reutzel-Edens

Scott Alan Frank

Carsten Weber

Alfio Borghese

Pamela Kaye Footman

Shella Lenyonga Tameze

Carsten Timpe

Alfio Lilly Development Centre S A Borghese

Carsten Lilly Forschung Gmbh Weber

Carsten Lilly Forschung Gmbh Timpe

Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed. 

[object Object]

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

Prodrugs of excitatory amino acids

The present invention provides novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making intermediates thereof.

Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone

This invention relates to synthetic excitatory amino acid prodrugs according to formula (I) and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders 

Growing community of inventors

Indianapolis, IN, United States of America

Steven Wayne Pedersen